Gsk Plc Stock Performance
| GLAXF Stock | USD 16.87 0.17 1.00% |
The company retains a Market Volatility (i.e., Beta) of 0.15, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GSK Plc's returns are expected to increase less than the market. However, during the bear market, the loss of holding GSK Plc is expected to be smaller as well. At this point, GSK plc has a negative expected return of -0.34%. Please make sure to check out GSK Plc's total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if GSK plc performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GSK plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 3.8 B |
GSK |
GSK Plc Relative Risk vs. Return Landscape
If you would invest 2,146 in GSK plc on September 15, 2024 and sell it today you would lose (459.00) from holding GSK plc or give up 21.39% of portfolio value over 90 days. GSK plc is currently producing negative expected returns and takes up 2.8043% volatility of returns over 90 trading days. Put another way, 24% of traded pink sheets are less volatile than GSK, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
GSK Plc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GSK Plc's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as GSK plc, and traders can use it to determine the average amount a GSK Plc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1199
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GLAXF |
Estimated Market Risk
| 2.8 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GSK Plc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GSK Plc by adding GSK Plc to a well-diversified portfolio.
GSK Plc Fundamentals Growth
GSK Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of GSK Plc, and GSK Plc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GSK Pink Sheet performance.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X | |||
| Price To Sales | 1.91 X | |||
| Revenue | 29.32 B | |||
| EBITDA | 8.8 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Book Value Per Share | 2.63 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 1.32 X | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (6.55 B) | |||
| Current Asset | 17.61 B | |||
| Current Liabilities | 18.14 B | |||
About GSK Plc Performance
By analyzing GSK Plc's fundamental ratios, stakeholders can gain valuable insights into GSK Plc's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GSK Plc has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GSK Plc has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Glaxosmithkline Plc is traded on OTC Exchange in the United States.Things to note about GSK plc performance evaluation
Checking the ongoing alerts about GSK Plc for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for GSK plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GSK plc generated a negative expected return over the last 90 days |
- Analyzing GSK Plc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GSK Plc's stock is overvalued or undervalued compared to its peers.
- Examining GSK Plc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GSK Plc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GSK Plc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GSK Plc's pink sheet. These opinions can provide insight into GSK Plc's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for GSK Pink Sheet analysis
When running GSK Plc's price analysis, check to measure GSK Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GSK Plc is operating at the current time. Most of GSK Plc's value examination focuses on studying past and present price action to predict the probability of GSK Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GSK Plc's price. Additionally, you may evaluate how the addition of GSK Plc to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |